Dice therapeutics 10q
WebPioneers in small molecule drug development. Our mission is to become an industry leader in creating transformative small molecule medicines for autoimmune and inflammatory … WebOct 11, 2024 · About DICE Therapeutics, Inc. ... risks and uncertainties described under the heading “Risk Factors” in the Company’s quarterly report on Form 10-Q filed on …
Dice therapeutics 10q
Did you know?
WebAbout – DICE THERAPEUTICS. We are led by an exceptional team of scientists, R&D executives and company builders with demonstrated track records of progressing … WebDec 31, 2024 · You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on …
WebOct 13, 2024 · Find the latest SEC Filings data for DICE Therapeutics, Inc. Common Stock (DICE) at Nasdaq.com. WebApr 1, 2024 · DICE Therapeutics Stock Performance. Shares of DICE opened at $28.67 on Friday. DICE Therapeutics has a 52-week low of $12.64 and a 52-week high of $45.99. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -13.40 and a beta of 0.71. The business's fifty day moving average is $29.47 and its 200-day moving average is …
WebMar 30, 2024 · Posted by ABMN Staff on Mar 30th, 2024. DICE Therapeutics, Inc. ( NASDAQ:DICE – Get Rating) Director Ra Capital Management, L.P. purchased 155,089 shares of the company’s stock in a transaction that occurred on Thursday, March 23rd. The shares were purchased at an average cost of $26.67 per share, with a total value of … WebMar 28, 2024 · DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in ...
WebNov 9, 2024 · The Investor Relations website contains information about DICE Therapeutics's business for stockholders, potential investors, and financial analysts.
WebDICE Therapeutics. 4,014 followers. 7mo. We are pleased to announce the completion of enrollment in our Phase 1 clinical trial of DC-806. DC-806 is an orally-available, small molecule antagonist ... grammar \u0026 composition i/of people test 05WebSep 30, 2024 · false Q3--12-31 0001645569 P2Y P2M P4Y P6Y1M6D P6Y1M6D P5Y6M P6Y1M6D P5Y6M P6Y1M6D 0.75 0.80 0.0074 0.0074 0.0042 0.0082 0.0110 0.0173 P9Y11M12D P9Y11M12D P5Y P6Y8M12D P5Y P6Y8M12 china slim fit golf shirtsWebMar 21, 2024 · About DICE Therapeutics, Inc. ... risks and uncertainties described under the heading “Risk Factors” in the Company’s quarterly report on Form 10-Q filed on November 12, 2024, and its other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by … grammar tutorial softwareWebDICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings) IRS No.: 472286244 State of Incorp.:DE Fiscal Year End: 1231 Type: S-1MEF Act: 33 ... grammar\\u0026writing 1 2nd edition 답지WebSep 11, 2024 · Summary. Dice Therapeutics has filed to raise $160 million in an IPO of its common stock. The firm is developing treatments for immune system diseases and other serious health conditions. grammar tutorial youtubeWebApr 10, 2024 · According to 15 analysts, the average rating for DICE stock is "Buy." The 12-month stock price forecast is $63.97, which is an increase of 138.43% from the latest price. grammar tutorial forming questions in spanishWebMar 15, 2024 · Inside Dice Therapeutics, Inc.'s 10-K Annual Report: Financial - Income Highlight. The increase of $5.1 million was primarily due to interest income earned on … grammar tutorial online free